Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

New nonpeptide compound AY-0068 is a potent, selective and metabolically stable tryptase inhibitor

Jan. 4, 2000

Inspire and UNC describe method of enhancing airways mucus secretion

Jan. 4, 2000

Avanir's new benzimidazole analogues inhibit IgE response to allergens

Jan. 4, 2000

Preclinical pharmacokinetics of SB-240563 support clinical development for asthma

Jan. 3, 2000

CFC-free flunisolide to be developed by 3M/Forest partnership

Jan. 3, 2000

Specific VLA-4 inhibitor designed at Biogen for cell adhesion-mediated pathologies

Jan. 3, 2000

FDA approves new treatment for respiratory failure in neonates

Dec. 30, 1999

Asthma symptoms improve significantly, steroid use decreases in patients on anti-IgE therapy

Dec. 28, 1999

Genentech and Inspire enter respiratory therapeutics collaboration

Dec. 27, 1999

Genome Therapeutics achieves milestone in asthma genomics alliance with Schering-Plough

Dec. 23, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...